Leukemia is the medical term for a type of cancer that begins in the blood-forming cells of the bone marrow and then gradually spreads to other organs. Chronic lymphocytic leukemia or CLL is a type of cancer that originates in the lymphocytes (white blood cells) within the bone marrow. Eventually, the cancer moves into the blood. As CLL is chronic in nature, the disease typically progresses at a slow pace, especially when compared with other types of cancer.
Read More: Drug development over the last 60 years
Chronic lymphocytic leukemia accounts for about one-quarter of new cases of leukemia and it primarily affects older adults. According to the American Cancer Society, the average age of the patient at the time of diagnosis is around 71 years. Seldom seen in those under the age of 40, CLL is a rare development amongst children.
It is due to the high incidence of CLL that the global CLL therapeutics market has been experiencing rapid growth over the past few years. Along with the rising number of CLL patients, unmet medical needs and special provisions granted to orphan drugs are also reasons why the industry is growing. According to analysts at Technavio, the global CLL therapeutics market, which stood at $2.21 billion in 2015, will reach approximately $5 billion by 2020, recording a CAGR of 19%.
*Johnson & Johnson figures do not include sales from consumer products
Top 15 Companies in the Global CLL Therapeutics Market
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche is a healthcare company that operates through two business lines: pharmaceuticals and diagnostics. With offerings like MabThera/Rituxan, Venclexta, and Gazyva, the company has made made its mark in the global CLL therapeutics market. In January 2015, the F.Hofmann-La Roche and Foundation Medicine entered into a strategic collaboration to identify and develop novel treatments for cancer.
A global biopharmaceutical company, Abbvie develops and markets advanced therapies that treat chronic autoimmune diseases, including psoriasis, rheumatoid arthritis, Crohn’s disease, human immunodeficiency virus, hepatitis C, thyroid disease, endometriosis, and Parkinson’s disease. The company has also established its presence in the global CLL therapeutics market with offerings like Imbruvica.
Incorporated in 1994, Teva is an Israeli-American multinational pharmaceutical company. The company operates in 60 countries and offers generic medicines and specialty pharmaceutical products. Treanda and Bendeka are its major offerings in the global CLL therapeutics market.
Established in 1887, Johnson & Johnson focuses on research, development, and sale of products across various therapy areas, including immunology, infectious diseases, oncology, neuroscience, and metabolic and cardiovascular diseases. It also develops and sells medical devices and consumer care products.
An American research-based biopharmaceutical company, Gilead Sciences focuses on the discovery, development, and commercialization of innovative medicines. It has established its presence in the global CLL therapeutics market with Zydelig.
Founded in 1996, Novartis is headquartered in Basel, Switzerland. The company is involved in the research, manufacturing, and marketing of healthcare products worldwide; has made its presence in the global CLL therapeutics market with medicines like Arzerra.
A biotechnology company, ZIOPHARM Oncology employs novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer and auto-immune diseases like graft-versus-host-disease (GvHD). CAR/ Cytokine is its major pipeline cancer treatment product.
XEME Biopharma, a clinical-stage company, is focused on developing therapeutic products under the guidance of the Food and Drug Administration (FDA) in the area of active cancer immunotherapy (vaccines). Oncoquest is its primary drug offering used to fight cancer.
A biopharmaceutical company, TG Therapeutics focuses on the development of novel treatments for B-cell malignancies and autoimmune diseases. It acquires, develops, and commercializes pharmaceutical products for the treatment of cancer and other underserved therapeutic needs.
Regeneron is a New York based biotechnology company that discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions across the globe.
Based out of Japan, Ono Pharmaceutical manufactures and sells pharmaceuticals across various therapy areas, including cancer. ONO-4059 is its major offering in the global CLL therapeutics market.
A biotechnology company, Molecular Templates focuses on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers and other serious diseases. One of its upcoming offerings in the global CLL therapeutics market is MT-3724.
Ligand is a biopharmaceutical company which focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Evomela and Dinaciclib are its major offerings when it comes to cancer treatment.
An American biotechnology company, Genzyme is recognised for its pioneering work in the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. Tio date it has discovered and developed products and services primarily in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases, and endocrinology.
A biopharmaceutical company, Arno Therapeutics focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. Onapristone, AR-42 and AR-12 are some of its major pipeline products.
View the 2016-2020 Global Chronic Lymphocytic Leukemia Therapeutics Market Report
